GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
A1987 Ki164256 CitationTarget: LPA ReceptorsSummary: LPA receptor antagonist -
A5318 Prazosin HClSummary: α1 and α2B-adrenoceptor antagonist -
A5375 TranilastSummary: Angiogenesis inhibitor -
A5355 VenlafaxineSummary: Dual serotonin/noradrenalin re-uptake inhibitor -
A5173 Alfuzosin HClSummary: α1-adrenergic receptor antagonist -
A5294 Sumatriptan SuccinateTarget: 5-HT1 ReceptorsSummary: 5-HT1 receptor agonist -
A5350 Ziprasidone HClSummary: Serotonin and dopamine receptor antagonist -
A5399 IloperidoneSummary: Dopamine (D2) and serotonin (5HT2) receptor antagonist -
A5489 Zibotentan (ZD4054)1 CitationSummary: ETA receptor antagonist,potent and specific -
A5827 AM12412 CitationSummary: Cannabinoid CB2 receptor agonist,potent and selective

